Trial Profile
Mini-allografting to complement treatment with glivec (Imatinib - formerly known as STI571) to eradicate minimal residual disease (MRD) in chronic myeloid leukaemia (CML) patients aged 65 years and under with matched sibling donors: a randomised controlled trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 May 2018
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 24 Feb 2006 New trial record.